ArticleFrontiers in neurology2025
Platelet-to-high-density lipoprotein cholesterol ratio as a predictor of stroke risk: a longitudinal analysis of the China health and retirement longitudinal study.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of platelet to highdensity lipoprotein cholesterol ratio (PHR) with stroke and its subtypes: a large prospective cohort study.Scientific reports · 2026Article
- Platelet to high-density lipoprotein cholesterol ratio predicts clinical outcomes after acute ischemic stroke: a prospective cohort study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stroke is a major health concern in aging populations. This study investigates the platelet-to-high-density lipoprotein cholesterol ratio (PHR) as a predictor of stroke risk in middle-aged and older Chinese adults. Methods: We analyzed data from 8,405 participants aged ≥45 years in the China Health and Retirement Longitudinal Study (CHARLS), with an 8-year follow-up. PHR was calculated from baseline blood samples. Multivariate logistic regression models, supplemented by smooth curve fitting to assess dose-response relationships and subgroup analyses with interaction testing, assessed the association between PHR and stroke incidence, adjusting for various factors. Results: During follow-up, 753 (8.96%) participants reported a stroke. Smooth curve fitting visually confirmed a linear dose-response relationship between PHR and stroke probability. Each standard deviation increase in PHR was associated with 17% higher odds of stroke (OR: 1.17; 95% CI: 1.08-1.26, Conclusion: Elevated PHR is independently associated with increased stroke risk in middle-aged and older Chinese adults. Incorporating PHR into existing risk assessment tools may enhance stroke risk stratification and guide preventive strategies. Further research is needed to elucidate underlying mechanisms and validate findings in diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.